Cassava Sciences (FLNA) Stock Price, News & Analysis

Company Overview

Cassava Sciences, Inc. is a biotechnology company focused on developing treatments for neurodegenerative diseases. The company’s research has centered on filamin A, a scaffolding protein that Cassava believes may play a role in Alzheimer’s disease and other neurological conditions.

Its primary investigational product was simufilam, an oral therapy studied for potential use in patients with Alzheimer’s disease. Cassava also developed SavaDx, an experimental diagnostic intended to detect Alzheimer’s disease using a small blood sample. These products were investigational and were not established as approved commercial treatments.

Founded in 1998 and headquartered in Austin, Texas, Cassava Sciences historically conducted research and clinical development activities in the United States, with clinical studies involving participants in multiple countries. The company was led for many years by founder Remi Barbier, who served as chief executive officer. The ticker provided in the request, NASDAQ:FLNA, does not correspond to Cassava Sciences; Cassava Sciences has historically traded under the symbol NASDAQ:SAVA.

Key Stats

• Today's Range: $0.78 to $0.81
• 50-Day Range: $0.68 to $1.03
• 52-Week Range: $0.67 to $4.98
• Volume: 222,724 shs
• Average Volume: 1.03 million shs
• Market Capitalization: $38.29 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $5.00
• Consensus Rating: Hold

Cassava Sciences Stock Analysis - MarketRank™

Cassava Sciences scored higher than 58% of companies evaluated by MarketBeat, and ranked 366th out of 884 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.2 / 5
• Analyst Rating: Hold

Consensus Rating

Cassava Sciences has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, 1 buy rating, no hold ratings, and 1 sell rating.

Upside Potential

Cassava Sciences has a consensus price target of $5.00, representing about 541.1% upside from its current price of $0.78.

Amount of Analyst Coverage

Cassava Sciences has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Cassava Sciences is -0.90, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Cassava Sciences is -0.90, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Cassava Sciences has a P/B Ratio of 0.51. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

13.49% of the float of Cassava Sciences has been sold short.

Short Interest Ratio / Days to Cover

Cassava Sciences has a short interest ratio ("days to cover") of 18.69, which indicates bearish sentiment.

Change versus previous month

Short interest in Cassava Sciences has recently decreased by 1.19%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Cassava Sciences does not currently pay a dividend.

Dividend Growth

Cassava Sciences does not have a long track record of dividend growth.

News and Social Media

• Score: 3.7 / 5
• News Sentiment: 0.98

News Sentiment

Cassava Sciences has a news sentiment score of 0.98. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.40 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 5 news articles for Cassava Sciences this week, compared to 2 articles on an average week.

MarketBeat Follows

6 people have added Cassava Sciences to their MarketBeat watchlist in the last 30 days. This is an increase of 50% compared to the previous 30 days.

Company Ownership

• Score: 3.5 / 5
• Insider Trading: Acquiring Shares

Net Insider Buying

Over the last three months, insiders have purchased a net $356,328.00 in company stock, which represents 0.9457% of the company's market cap.

Insider Buying vs. Insider Selling

In the past three months, Cassava Sciences insiders have bought more of their company's stock than they have sold. Specifically, they have bought $356,328.00 in company stock and sold $0.00 in company stock.

Percentage Held by Insiders

4.60% of the stock of Cassava Sciences is held by insiders.

Percentage Held by Institutions

38.05% of the stock of Cassava Sciences is held by institutions.

Company Calendar

• Last Earnings: 7/29/2026
• Today: 10/08/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: NASDAQ:FLNA
• Previous Symbol: NASDAQ:SAVA
• CIK: 1069530
• Web: cassavasciences.com
• Phone: 512-501-2444
• Fax: 512-501-0414
• Employees: 30
• Year Founded: 1998

Price Target and Rating

• Average Price Target for Cassava Sciences: $5.00
• High Price Target: $5.00
• Low Price Target: $5.00
• Potential Upside/Downside: +536.9%
• Consensus Rating: Hold
• Rating Score (0-4): 2.00
• Research Coverage: 2 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.87)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$90.97 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -58.78%
• Return on Assets: -36.74%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 2.08
• Quick Ratio: 2.08

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.54 per share
• Price / Book: 0.51

Miscellaneous

• Outstanding Shares: 48,310,000
• Free Float: 46,086,000
• Market Cap: $37.92 million
• Optionable: Optionable
• Beta: -0.65